AngioDynamics Expands NanoKnife Indications Across Europe

February 19, 2026—AngioDynamics, Inc. announced expanded European indications for its NanoKnife system with irreversible electroporation (IRE) technology to include soft tissue ablation of tumors of the liver, pancreas, kidney, and prostate, including use in patients with intermediate-risk prostate cancer, according to a company press release.

The update broadens access to the NanoKnife IRE technology across several major solid tumor types. The technology is designed to destroy tumor cells while preserving surrounding critical structures such as blood vessels, bile ducts, and nerves, making it particularly suited for tumors located in complex anatomic regions such as the pancreas and liver.

“The expansion of additional organ indications in Europe underscores the broader potential of IRE technology and strengthens NanoKnife as a scalable platform for complex tumor ablation,” said Laura Piccinini, Senior Vice President and General Manager, Cardiovascular & International at AngioDynamics, in the release. “Our goal is to ensure physicians have access to differentiated tools that expand treatment options for patients across multiple disease states.”

According to AngioDynamics, there is a growing body of clinical evidence that supports IRE across metastatic colorectal cancer, liver and pancreatic cancer, hepatocellular carcinoma, and renal tumors, including comparative and real-world analyses that have reinforced the safety profile and expanding clinical utility of IRE in anatomically challenging disease states.